Source:http://linkedlifedata.com/resource/pubmed/id/15025795
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2004-3-17
|
pubmed:abstractText |
The causes of interpatient variation in severe toxicity resulting from treatment with weekly 5-fluorouracil (5-FU)/ leucovorin (LV) are poorly understood. This study was undertaken to examine the contribution of commonly occurring polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene to interpatient variability in 5-FU pharmacokinetics and toxicity. Patients with stage III/IV colorectal cancer were treated by bolus intravenous (I.V.) injection with 500 mg/m2 doses of 5-FU and LV once every week. The pharmacokinetics of 5-FU was determined on weeks 1 and 4. Genotyping assays were developed for 8 polymorphisms in the DPYD gene. A well-characterized functional polymorphism in the 5' untranslated region of the thymidylate synthase (TS) gene was also analyzed. A cohort of 22 patients (15 male, 7 female) with a median age of 61 years was evaluated. Although there was no relationship between the area under the plasma concentration time curve (AUC) for the first dose of 5-FU and worst-grade toxicity during the first cycle of therapy, 3 of the 4 patients in whom the AUC on week 4 was more than equal to 5 microgram/h/mL greater than the value for the first dose experienced grade 3/4 toxicity during subsequent treatment. Among the 8 polymorphisms in the DPYD gene, 7 were found to vary in the study population but none were significantly associated with the AUC of 5-FU. There was no relationship between the DPYD and TS genotypes examined and 5-FU toxicity. Extensive polymorphism in the DPYD gene was observed; however, no conclusive correlations existed between the DPYD and TS genotype and 5-FU pharmacokinetics or toxicity. Decreases in 5-FU clearance in certain patients may provide insight into the increased toxicity following repetitive cycles of treatment with weekly I.V. bolus 5-FU. The present study offers useful themes for undertaking larger prospective pharmacogenetic studies in the future.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrouracil Dehydrogenase (NADP),
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1533-0028
|
pubmed:author |
pubmed-author:ChabnerBruce ABA,
pubmed-author:CharlatOlgaO,
pubmed-author:ClarkJeffrey WJW,
pubmed-author:KreconusElaineE,
pubmed-author:NesbittStevenS,
pubmed-author:PatrickKellyK,
pubmed-author:PuchalskiThomas ATA,
pubmed-author:RyanDavid PDP,
pubmed-author:StantonVincent PVPJr,
pubmed-author:SupkoJeffrey GJG,
pubmed-author:ZhuAndrew XAX
|
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
225-34
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:15025795-Adult,
pubmed-meshheading:15025795-Aged,
pubmed-meshheading:15025795-Aged, 80 and over,
pubmed-meshheading:15025795-Antineoplastic Agents,
pubmed-meshheading:15025795-Colorectal Neoplasms,
pubmed-meshheading:15025795-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:15025795-Female,
pubmed-meshheading:15025795-Fluorouracil,
pubmed-meshheading:15025795-Humans,
pubmed-meshheading:15025795-Leucovorin,
pubmed-meshheading:15025795-Male,
pubmed-meshheading:15025795-Middle Aged,
pubmed-meshheading:15025795-Pharmacogenetics,
pubmed-meshheading:15025795-Polymorphism, Genetic,
pubmed-meshheading:15025795-Thymidylate Synthase
|
pubmed:year |
2004
|
pubmed:articleTitle |
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
|
pubmed:affiliation |
Massachusetts General Hospital, Division of Hematology/Oncology, Harvard Medical School, Boston, MA, USA. azhu@partners.org
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|